The performance of International HIV dementia Scale (IHDS) versus Mini Mental Status Examition Scale (MMSE) in assessment of HIV-associated Neurocognitive Disorders (HAND) among HIV-Infected Tanzanian adults: a Case-Control Study
Keywords:HIV-associated neurocognitive deficits, Mini-Mental Status Examination, International HIV Dementia Scale
Availability of HAART has improved the outcome of HIV-associated neurocognitive disorders (HAND) though the prevalence is still high. Routine screening for HAND may offer room for early detection and prompt management that may improve overall outcome.
To compare the performance of International HIV dementia scale (IHDS) and Mini Mental Status Examination (MMSE) Scale in assessing HIV-associated neurocognitive disorders.
This was a case- control study involving 351 HIV-cases and 150 HIV-negative controls. International HIV dementia scale and Mini Mental Status Examination scale were used to screen for neurocognitive deficits.
For cases, 91(25.9%) were males and 260(74.1%) were females while for 150 controls, 38(25.3%) were males and 112 (74.7%) were females. Under IHDS score 240(68.4%) of cases had HAND compared to 10(2.8%) when MMSE was used. The mean scores under MMSE for cases was 29±1.7 compared to 29.3± 1.2 for controls (p = 1.00). The mean IHDS scores for cases was 9.35 ± 1.89 compared to 10.35±0.89 (p < 0.0001) for controls.
Our findings suggests that IHDS has better sensitivity in detecting cases of HAND and perform better in identifying HIV/AIDS cases that requires further cognitive evaluation on comprehensive neuropsychological batteries.
Gulick RM. Antiretroviral treatment 2010: progress and controversies. J Acquir Immune Defic Syndr 1999. 2010 Dec;55 Suppl 1:S43–8.
Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, et al. Neurologic disease burden in treated HIV/AIDS predicts survival. Neurology. 2010 Sep 28;75(13):1150–8.
Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010 Dec 7;75(23):2087–96.
Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789–99.
Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002 Dec 24;59(12):1944–50.
Albert SM, Weber CM, Todak G, Polanco C, Clouse R, McElhiney M, et al. An Observed Performance Test of Medication Management Ability in HIV: Relation to Neuropsychological Status and Medication Adherence Outcomes. AIDS Behav. 1999 Jun;3(2):121–8.
Heaton RK, Velin RA, McCutchan JA, Gulevich SJ, Atkinson JH, Wallace MR, et al. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med. 1994 Feb;56(1):8–17.
Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc JINS. 2004 May;10(3):317–31.
Woods SP, Iudicello JE, Moran LM, Carey CL, Dawson MS, Grant I. HIV-associated Prospective Memory Impairment Increases Risk of Dependence in Everyday Functioning. Neuropsychology. 2008 Jan;22(1):110–7.
Trépanier LL, Rourke SB, Bayoumi AM, Halman MH, Krzyzanowski S, Power C. The impact of neuropsychological impairment and depression on health-related quality of life in HIV-infection. J Clin Exp Neuropsychol. 2005 Jan;27(1):1–15.
Oshinaike OO, Akinbami AA, Ojo OO, Ojini IF, Okubadejo UN, Danesi AM. Comparison of the Minimental State Examination Scale and the International HIV Dementia Scale in Assessing Cognitive Function in Nigerian HIV Patients on Antiretroviral Therapy. AIDS Res Treat [Internet]. 2012 [cited 2015 Sep 27];2012. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463159/
Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirology Off Publ Int Retrovirology Assoc. 1995 Mar 1;8(3):273–8.
Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS Lond Engl. 2005 Sep 2;19(13):1367–74.
Our Profile - MUHIMBILI NATIONAL HOSPITAL [Internet]. [cited 2016 Feb 26]. Available from: http://www.mnh.or.tz/index.php/our-profile
Dar es Salaam. In: Wikipedia, the free encyclopedia [Internet]. 2016 [cited 2016 Feb 26]. Available from: https://en.wikipedia.org/w/index.php?title=Dar_es_Salaam&oldid=706161663
HU X, ZHOU Y, LONG J, FENG Q, WANG R, SU L, et al. Diagnostic accuracy of the International HIV Dementia Scale and HIV Dementia Scale: A meta-analysis. Exp Ther Med. 2012 Oct;4(4):665–8.
SCLAFANI VD, MACKAY RDS, MEYERHOFF DJ, NORMAN D, WEINER MW, FEIN G. Brain atrophy in HIV infection is more strongly associated with CDC clinical stage than with cognitive impairment. J Int Neuropsychol Soc JINS. 1997 May;3(3):276–87.
Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. 2009 Apr;10(4):246–52.
Ganasen KA, Fincham D, Smit J, Seedat S, Stein D. Utility of the HIV Dementia Scale (HDS) in identifying HIV dementia in a South African sample. J Neurol Sci. 2008 Jun 15;269(1-2):62–4.
Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for Cognitive Impairment in Human Immunodeficiency Virus. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011 Oct 15;53(8):836–42.
Poutiainen E, Elovaara I, Raininko R, Hokkanen L, Valle SL, Lähdevirta J, et al. Cognitive performance in HIV-1 infection: relationship to severity of disease and brain atrophy. Acta Neurol Scand. 1993 Feb;87(2):88–94.
Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep. 2011 Mar;8(1):54–61.